Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.


A call to adapt the regulation of HLA testing for T cell receptor-based therapeutics

Access options

Rent or buy this article

Prices vary by article type



Prices may be subject to local taxes which are calculated during checkout

Nature Reviews Drug Discovery 23, 1-2 (2024)



  1. Nathan, P. et al. Overall survival benefit with tebentafusp in metastatic uveal melanoma. N. Engl. J. Med. 385, 1196–1206 (2021).

    Article  PubMed  Google Scholar 

  2. Hong, D. S. et al. Autologous T cell therapy for MAGE-A4+ solid cancers in HLA-A*02+ patients: a phase 1 trial. Nat. Med. 29, 104–114 (2023).

    Article  PubMed  Google Scholar 

  3. Directorate-General for Health and Food Safety. MDCG 2022-2 - Guidance on general principles of clinical evidence for In Vitro Diagnostic medical devices (IVDs). European Commission (2022).

Download references

Supplementary Information

  1. Supplementary information

Competing Interests

The authors declare competing interests, including working for companies that are developing TCR-based therapies. Please see Supplementary information for further details.

Nature Careers


Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing


Quick links